CLOs on the Move

Boundless Bio

www.boundlessbio.com

 
Boundless Bio, a San Diego based company backed by ARCH Venture Partners, is discovering and developing novel cancer therapeutics based on the role of extrachromosomal DNA (ecDNA) in driving tumorigenesis, resistance and recurrence. When DNA in cancer cells comes off chromosomes, “extrachromosomal DNA (ecDNA),” it becomes unbound and unwound, thereby enabling numerous copies of cancer-causing genes, driving cancer cells to grow and allowing them to resist treatment. At Boundless Bio, we are counterattacking this ecDNA phenomenon with boundless innovation and boundless energy to develop powerful new cancer medicines that eliminate cancer cells’ ability to employ ecDNA to survive.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.boundlessbio.com
  • 11099 North Torrey Pines Road Suite 280
    La Jolla, CA USA 92037
  • Phone: 858.766.9912

Executives

Name Title Contact Details
Rebecca Jones
Associate General Counsel Profile
Jessica Oien
General Counsel and Corporate Secretary Profile

Similar Companies

ONBIO

ONBIO Inc. is a Richmond Hill, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

International Drug Development Institute

International Drug Development Institute is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ariana Pharma

Ariana is a spin-off of the prestigious Pasteur Institute offering a unique and powerful association rules-based analytical approach to clinical datasets and biomarker discovery that is complementary to statistical analysis.

SalioGen Therapeutics

SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative non-viral gene therapy.

Color Genomics

Color provides a high-quality, physician-ordered, genetic test at a low cost. We include support for physicians, as well as genetic counseling as part of every purchase. Our goal is to expand physician-supported access to genetic testing for hereditary cancer risk to every person, everywhere.